Holen Sie sich die Stockscreener-App
31.94
1.72%
-0.56
Handel nachbörslich:
31.96
0.02
+0.06%
Schlusskurs vom Vortag:
$32.50
Offen:
$32.5
24-Stunden-Volumen:
289.63K
Relative Volume:
0.63
Marktkapitalisierung:
$1.62B
Einnahmen:
$413.05M
Nettoeinkommen (Verlust:
$-27.67M
KGV:
-56.93
EPS:
-0.561
Netto-Cashflow:
$-30.75M
1W Leistung:
+5.00%
1M Leistung:
+12.90%
6M Leistung:
-2.77%
1J Leistung:
-3.27%
1-Tages-Spanne:
$31.82
$34.01
1-Wochen-Bereich:
$30.05
$34.01
52-Wochen-Spanne:
$27.55
$40.71
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Firmenname
Immunocore Holdings Plc Adr
Sektor
Branche
Telefon
01235 5430281
Adresse
90 PARK DRIVE, OXFORDSHIRE
Compare IMCR vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
31.94 | 1.61B | 413.05M | -27.67M | -30.75M | -0.561 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2026-01-07 | Hochstufung | UBS | Sell → Buy |
| 2025-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2025-09-18 | Fortgesetzt | Guggenheim | Neutral |
| 2025-08-25 | Fortgesetzt | Jefferies | Buy |
| 2025-05-27 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Sell |
| 2024-10-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-11-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-13 | Eingeleitet | Needham | Buy |
| 2023-08-16 | Eingeleitet | CapitalOne | Overweight |
| 2023-07-17 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-03-30 | Eingeleitet | Guggenheim | Buy |
| 2023-03-24 | Eingeleitet | Bryan Garnier | Buy |
| 2022-12-16 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-30 | Eingeleitet | Barclays | Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-08-08 | Eingeleitet | Cowen | Outperform |
| 2022-08-02 | Eingeleitet | BTIG Research | Buy |
| 2022-02-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-20 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Neutral |
| 2021-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Immunocore Holdings Plc Adr Aktie (IMCR) Neueste Nachrichten
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why - TradingView
Is it a good idea to invest in Immunocore stock right now? - MSN
Here's Why You Should Add ANIX Stock to Your Portfolio Now - TradingView
Reasons Why Investors Should Consider Betting on Indivior Stock - TradingView
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib - TradingView
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria - TradingView
PFE Stock Slides Following CFO Exit, 2026 Guidance Reaffirmed - TradingView
IMCR News | IMMUNOCORE HOLDINGS PLC-ADR (NASDAQ:IMCR) - ChartMill
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies - TradingView
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It? - TradingView
Is it a Good Idea to Invest in Immunocore Stock Right Now? - TradingView
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised) - TradingView
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up - TradingView
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure - TradingView
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review - TradingView
INDV Stock: What Sublocade Growth Signals for 2026 - TradingView
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder - TradingView
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why - TradingView
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US - TradingView
Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results - TradingView
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs - TradingView
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week? - TradingView
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know - TradingView
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data - TradingView
Amgen Secures EU Nod for Imdylltra in Lung Cancer Indication - TradingView
MRNA Partners With CEPI to Develop Vaccine for Bundibugyo Ebolavirus - TradingView
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug - TradingView
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes - TradingView
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma - GlobeNewswire Inc.
Immunocore reports Phase 1 data for melanoma drug brenetafusp - Investing.com
TGTX's Single-Dose Briumvi Hits Bioequivalence Goal in MS Study - TradingView
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy - TradingView
IMCRImmunocore Holdings plc ADR Stock Price and Quote - Finviz
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe - TradingView
Wall Street analysts think Immunocore (IMCR) could surge 111.53%: Read this before placing a bet - MSN
69,271 ADRs sale scheduled by Immunocore (NASDAQ: IMCR) - Stock Titan
Here's Why You Should Add Altimmune Stock to Your Portfolio Now - TradingView
Wall Street Analysts Think Immunocore (IMCR) Could Surge 111.53%: Read This Before Placing a Bet - Yahoo Finance
Immunocore Holdings (NASDAQ: IMCR) plans 65,000 ADR cashless sale - Stock Titan
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients - TradingView
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - TradingView
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know - TradingView
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know - TradingView
BMRN Stock Down on Mixed Results From Rare Disease Therapy Study - TradingView
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy - TradingView
Bayer Gets FDA Priority Review for Asundexian NDA in Stroke Prevention - TradingView
Roche's Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer - TradingView
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised - TradingView
T. Rowe Price (IMCR) holds 1.89M ADRs, files Schedule 13G/A amendment - Stock Titan
Immunocore Holdings stock (GB00BL963Z95): Recent price dip amid biotech trends - AD HOC NEWS
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y - TradingView
Finanzdaten der Immunocore Holdings Plc Adr-Aktie (IMCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):